Vanderbilt Institute for Therapeutic Advances

About

The Vanderbilt Institute for Therapeutic Advances represents the next frontier in translational biomedical research at Vanderbilt. One where curiosity-driven discovery is seamlessly integrated with real-world impact. VITA reinforces our commitment to supporting faculty who want to push boundaries, develop new therapies, and change the way we approach human health.

Leadership

The Vanderbilt Institute for Therapeutic Advances is led by scientific director Craig Lindsley, William K. Warren, Jr. Chair in Medicine and Executive Director of the Warren Center for Neuroscience Drug Discovery.

A global leader in translational pharmacology, Lindsley holds over 130 U.S. patents and has developed more than 20 clinical candidates, including first-in-class therapeutics targeting CNS disorders. As Editor-in-Chief of Journal of Medicinal Chemistry, he continues to shape the future of drug development and innovation. Learn more about VITA leadership and the Scientific Advisory Board shaping the institute’s future.

VITA will operate at the convergence of science, data, and discovery. We’ve shown what’s possible with our neuroscience pipeline. Now we’re taking that model and applying it more broadly, embedding AI, leveraging genomics, and breaking open new therapeutic areas. Our goal is clear: to generate more shots on goal, more clinical candidates, and ultimately, more cures.

Craig Lindsley
Scientific Director of the Vanderbilt Institute for Therapeutic Advances